C91 Category · further specificity required Lymphoid leukemia
ICD-10-CM C91 identifies “Lymphoid leukemia” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 2: Neoplasms
Code-level instructions
Excludes 11
personal history of leukemia (Z85.6)
Inherited instructions
Chapters 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C81-C96 · Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
More specific codes
C91.0Acute lymphoblastic leukemia [ALL]Category · further specificity requiredC91.1Chronic lymphocytic leukemia of B-cell typeCategory · further specificity requiredC91.3Prolymphocytic leukemia of B-cell typeCategory · further specificity requiredC91.4Hairy cell leukemiaCategory · further specificity requiredC91.5Adult T-cell lymphoma/leukemia (HTLV-1-associated)Category · further specificity requiredC91.6Prolymphocytic leukemia of T-cell typeCategory · further specificity requiredC91.9Lymphoid leukemia, unspecifiedCategory · further specificity requiredC91.AMature B-cell leukemia Burkitt-typeCategory · further specificity requiredC91.ZOther lymphoid leukemiaCategory · further specificity requiredOfficial index references
References from other codes (8)
Excludes 1 · leukemia (C91-C95)
Excludes 1 · leukemia (C91.-, C92.-, C93.-, C94.-, C95.-)
Code first · leukemia (C91-C95)
Code first · leukemia (C91-C95)
Code first · leukemia (C91-C95)
Excludes 1 · leukemia (C91-C95)
Inclusion terms · Conditions classifiable to C91-C95
Inclusion terms · Conditions classifiable to C91-C95
History
Code history
No recorded change since first observation
Effective from
- First observed
Lymphoid leukemia
Category — select a more specific code
CDC/NCHS · FY2016All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.